Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Recordati Industria Chimica e Farmaceutica

Investor Presentation • Jul 27, 2017

4056_ir_2017-07-27_2ce55fde-4d3b-4596-95a0-fc601eb9ecef.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

2017 First half results

CONFERENCE CALL – 27 JULY 2017

First half 2017 highlights

  • •Revenue € 650.9 million, up 10.7%
  • •EBITDA € 224.0 million or 34.4% of sales, up 19.1%
  • •Operating income (EBIT) € 203.2 million or 31.2% of sales, up 19.4%
  • •Net income € 147.0 million or 22.6% of sales, up 19.8%
  • • Net debt € 356.3 million, an increase of € 157.5 million as compared to year‐end 2016, after dividend distribution and product acquisition for an overall disbursement of € 324.9 million.
  • •Approval of Cystadrops® for the ocular manifestations of cystinosis
  • •Agreement with the Meyer Hospital in Florence for the development of a treatment for ROP
  • • Acquisition of the European rights to Seloken®/Seloken® ZOK (metoprolol) and Logimax® (metoprolol+felodipine) from AstraZeneca
  • •Private placement of notes for a total of € 125.0 million
  • •Agreement with MimeTech for the development of a new compound for neurotrophic keratitis
  • •Approval of Reagila® (cariprazine) for the treatment of schizophrenia

Main product sales

Corporate products including drugs for rare diseases account for 64.6% of revenue

(
l
l
)
i
i
E
m
o
n
u
r
o		 1
H
2
0
1
7		 2
0
6
1
H
1		 h
C
%
a
n
g
e
(
)
d
®
l
d
i
i
i
i
i
Z
a
n
p
e
r
c
a
n
p
n
e		 6
9
2		 6
3
7		 8
7
®
(
)
l
d
l
l
i
i
i
i
i
Z
+
a
n
p
r
e
s
s
e
r
c
a
n
p
n
e
e
n
a
a
p
r		 3
6
3		 3
0
5		 3
9
(
)
®
l
d
i
i
U
r
o
r
e
c
s
o
o
s
n		 4
6
5		 4
2
7		 8
9
®
(
)
L
i
i
i
t
t
t
v
a
z
o
p
a
v
a
s
a
n		 9
1
4		 1
7
7		 9
5
*
h
d
O
t
t
t
e
r
c
o
r
p
o
r
a
e
p
r
o
c
s
u		 1
4
4
7		 1
1
9
0		 2
1
6
f
d
i
D
r
u
g
s
o
r
r
a
r
e
s
e
a
s
e
s		 1
0
4
1		 9
3
5		 9
2

3* Include the OTC corporate products for an amount of € 54.5 million in 2017 and € 40.3 million in 2016 (up 35.3%).

A diversified product portfolio

Data: First half 2017Total revenue € 650.9 m

Composition of revenue by geography

Continued growth

(
l
l
)
i
i
E
m
o
n
u
r
o		 1
H
2
0
1
7		 1
H
2
0
1
6		 h
%
C
a
n
g
e
l
I
t
a
y		 1
3
8
7		 1
1
8.
0		 1
7.
6
F
r
a
n
c
e		 6
0
1		 5
7.
2		 5.
0
h
d
k
R
i
C
I
S
i
U
i
t
t
s
s
a,
o
e
r
c
o
n
r
e
s
a
n
r
a
n
e
u
u		 6
4
5		 3
5.
7		 5
8.
0
U
S.
A		 5
4
7		 2.
8
5		 3.
5
G
e
r
m
a
n
y		 5
4
3		 4
8.
1		 1
3.
1
k
T
u
r
e
y		 4
5
7		 4
5.
1		 3
1.
S
i
p
a
n		 4
0
2		 3
7.
6		 7.
0
h
f
i
N
A
t
o
r
r
c
a		 2
3
1		 2
6.
7		 (
)
3.
3
1
l
P
t
o
r
g
a
u		 2
0
4		 1
9.
8		 3.
0
h
O
i
W
E
t
t
e
r
u
r
o
p
e
c
o
u
n
r
e
s		 2
5
6		 6.
8
1		 2.
0
5
h
O
C
E
E
i
t
t
e
r
c
o
u
n
r
e
s		 1
6
5		 1
6.
2		 2.
2
h
l
l
O
i
i
t
t
t
e
r
n
e
r
n
a
o
n
a
s
a
e
s		 9
9
1.		 9
2.
8		 (
)
0.
9
T
O
T
A
L
P
H
A
R
M
A
C
E
U
T
I
C
A
L
S		 6
2
7
7		 5
6
6.
7		 1
0.
8
P
H
A
R
M
A
C
E
U
T
I
C
A
L
C
H
E
M
I
C
A
L
S		 2
3
1		 2
1.
2		 9.
3
(
)
l
l
l
l
I
i
i
n
o
c
a
c
r
r
e
n
c
m
o
n
s
u
y,		 2
0
1
H
1
7		 1
H
2
0
1
6		 h
C
%
a
n
g
e
i
R
(
)
R
U
B
u
s
s
a		 2,
9
5
8
6		 2,
3
3
7.
4		 2
6.
6
k
T
(
)
T
R
Y
u
r
e
y		 1
6
9
2		 1
3
8.
3		 2
2.
3
U
S.
A
(
)
U
S
D		 6
1.
0		 6
0.
2		 1.
3

Geographical breakdown of pharmaceutical revenue

Pharmaceutical revenue € 627.7 m

First half 2017 results

Further margin growth

(
l
l
)
i
i
E
m
o
n
u
r
o		 1
H
2
0
1
7		 2
0
6
1
H
1		 h
C
%
a
n
e
g
R
e
v
e
n
u
e		 6
0
9
5		 5
8
7
9		 1
0
7
f
G
P
i
t
r
o
s
s
r
o		 4
5
4
1		 4
0
7
4		 1
1
5
f
%
a
s
o
r
e
v
e
n
u
e		 6
9
8		 6
9
3
S
G
&
A
E
p
e
n
s
e
s
x		 2
0
2
4		 8
0
1
7		 8
2
f
%
a
s
o
r
e
v
e
n
u
e		 3
1
1		 3
8
1.
&
R
D
E
p
e
n
s
e
s
x		 4
7
2		 4
1
6		 1
3
3
f
%
a
s
o
r
e
v
e
n
u
e		 7
2		 1
7
h
(
),
O
I
E
t
t
e
r
n
c
o
m
e
x
p
e
n
s
e
n
e		 (
)
1
4		 (
)
8
5		 (
)
8
3
4
f
%
a
s
o
r
e
v
e
n
u
e		 (
)
0
2		 (
)
1.
5
O
i
I
t
p
e
r
a
n
g
n
c
o
m
e		 2
0
3
2		 0
2
1
7		 9
1
4
f
%
a
s
o
r
e
v
e
n
u
e		 3
1
2		 2
9
0
N
I
t
e
n
c
o
m
e		 0
1
4
7		 1
2
2
7		 1
9
8
f
%
a
s
o
r
e
v
e
n
u
e		 2
2
6		 2
0
9

First half 2017 results

Net financial position

(
l
l
)
i
i
E
m
o
n
u
r
o		 3
0
J
2
0
1
7
n
e
u		 3
1
D
2
0
1
6
e
c		 h
C
a
n
g
e
h
d
h
f
l
C
i
i
t‐
t
a
s
a
n
s
o
r
e
r
m
n
a
n
c
a
i
t
t
n
v
e
s
m
e
n
s		 8
8
5		 1
3
8
5		 (
)
5
2
7
k
d
f
d
h
l
B
t
t‐
t
a
n
o
v
e
r
r
a
s
a
n
s
o
r
e
r
m
o
a
n
s		 (
)
1
9
9		 (
)
1
5
7		 (
)
4
2
d
h
i
i
L
t
o
a
n
s
e
n
o
n
e
e
a
r
u
w
y
–		 (
)
4
1
6		 (
)
0
4
4		 (
)
2
1
d
f
L
t
o
a
n
s
e
a
e
r
o
n
e
e
a
r
u
y
–		 (
)
3
8
0
5		 (
)
2
8
1
1		 (
)
9
9
4
C
O
S
O
N
E
T
F
I
N
A
N
I
A
L
P
I
T
I
N		 (
)
3
5
6
3		 (
)
1
9
8
8		 (
)
1
5
7
5

Financial projections

2017 targets

(
)
l
l
i
i
E
m
o
n
r
o
u		 2
0
1
6
l
A
t
c
u
a		 2
0
1
7
T
t
a
r
g
e
s
R
e
e
n
e
v
u		 1
1
5
4
,		 2
9
0
3
0
0
1
1
‐
,
,
E
B
I
T
D
A		 3
7
1		 4
5
0
4
6
0
‐
i
i
O
t
p
e
r
a
n
g
n
c
o
m
e
(
)
E
B
I
T		 3
2
7		 0
0
0
4
4
1
‐
N
I
t
e
n
c
o
m
e		 2
3
7		 2
9
0
2
9
5
‐

Company declarations, disclaimers and profile

DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY'S FINANCIAL REPORTS

The manager responsible for preparing the company's financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154‐bis of the Consolidated Law on Finance, that the accounting information contained in this presentation corresponds to the document results, books and accounting records.

Statements contained in this presentation, other than historical facts, are "forward‐looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward‐looking statements.

All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271) with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in the United States of America and in North Africa. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2016 is € 1,153.9 million, operating income is € 327.4 million and net income is € 237.4 million.

Contact Information Via M. Civitali 1 +39 02 48787393

Offices: Investor Relations: Website: Recordati S.p.A. Marianne Tatschke www.recordati.com 20148 Milano, Italy [email protected]

More from Recordati Industria Chimica e Farmaceutica

Transaction in Own Shares 2025
Dec 23
Transaction in Own Shares 2025
Dec 23
Share Issue/Capital Change 2025
Dec 16
Transaction in Own Shares 2025
Dec 16
Director's Dealing 2025
Dec 11
Director's Dealing 2025
Dec 10
Director's Dealing 2025
Dec 8
Transaction in Own Shares 2025
Dec 3
Regulatory Filings 2025
Nov 14
Regulatory Filings 2025
Nov 14
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.